BLLN
BillionToOne, Inc. Class AAbout BLLN
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Company
- Headquarters
- Menlo Park, CA
- Employees
- 713 (2026)
- Listed
- Nov 6, 2025
- Exchange
- Nasdaq
- Website
- billiontoone.com
- SEC industry
- Services-Medical Laboratories
- Cylvex sector
- Health Care · Diagnostics
Diagnostics
- Market cap #10 of 39
- P/B #6 of 37
Ranked highest first among stocks Cylvex covers.
- NTRANatera, Inc.$56.37B+0.63%
- IDXXIdexx Laboratories Inc$55.09B+4.06%
- LHLabcorp Holdings Inc.$29.86B+3.92%
- DGXQuest Diagnostics Inc.$28.21B+3.46%
- GHGuardant Health, Inc.$22.65B-3.54%
Financial summary
Related companies
About
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
From company filings and market data · Not investment advice
Price data
From daily bars
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.